Repare Therapeutics Inc. (CA) (Nasdq: RPTX)

https://www.reparerx.com

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-1664, a preclinical PLK4 inhibitor program; RP-3467, a preclinical Pol? inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com. *

	Start	2016-09-06 established
	Industry	CRISPR gene editing technology
	Industry 2	cancer drug

	Region	Montréal, QC
	Country	Canada
	Street	7210 Frederick-Banting Suite 100
	City	H4S 2A1 Montréal, QC
		Address record changed: 2024-02-15

Basic data	Employees	n. a.

		* Document for »About Section«: Repare Therapeutics Inc.. (1/25/24). "Press Release: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment". Cambridge, MA & Montréal.

		Record changed: 2024-02-15